Express Scripts champions $1 per pill access to an alternative for Daraprim
US pharmacy benefit manager Express Scripts (Nasdaq: ESRX) yesterday announced it will partner with Imprimis Pharmaceuticals (Nasdaq: IMMY) to drive access to a low-cost alternative to Daraprim (pyrimethamine), a drug for the treatment of toxoplasmosis that has been recently priced out of reach for people with HIV, pregnant women and others with weakened immune systems.
Imprimis is offering a compounded oral formulation of pyrimethamine and leucovorin (a form of folic acid) for $1 per capsule for people whose pharmacy benefit is managed by Express Scripts. While the 62-year-old Daraprim was priced $13.50 per pill earlier this year, its new owner, Turing Pharmaceuticals, made the decision in September to increase the price to $750 per pill. However, just last week, privately held Swiss drugmaker Turing announced plans to offer the drug at a significant price cut for US hospitals (The Pharma Letter November 26).
Program set to start as early as this week
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze